芪甲软肝丸治疗肝硬化代偿期疗效研究

Effect of Qijia Ruangan pill in the treatment of compensatory stage of liver cirrhosis

目的:评价芪甲软肝丸治疗肝硬化代偿期的临床疗效。方法:选取肝硬化代偿期患者100例,随机分为观察组50例、对照组50例。在常规治疗基础上,观察组加用芪甲软肝丸口服,对照组加用安络化纤丸口服,两组均治疗3个月。分别于治疗前后检测Fibroscan弹性值、脾长度、脾厚度、门静脉主干内径、脾静脉内径;检测谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)水平,评价中医症候积分及综合疗效。结果:观察组总有效率优于对照组(P<0.05)。治疗后观察组中医症候积分低于对照组(P<0.05)。治疗后观察组及对照组Fibroscan弹性值较治疗前降低,且观察组低于对照组(P<0.05)。治疗后观察组肝功能指标AST、TBIL、ALT较治疗前降低(均P<0.05),其中AST改善程度优于对照组(均P<0.05)。治疗后观察组肝脾超声门静脉内径、脾静脉内径、脾脏厚度、脾脏长度较治疗前降低(均P<0.05),且观察组门静脉内径数值改善程度优于对照组(均P<0.05)。结论:芪甲软肝丸能有效改善肝硬化代偿期患者肝功能、缓解临床症状、延缓肝硬化进程,且未见明显不良反应。

Objective:To evaluate the clinical efficacy of Qijia Ruangan pill in the treatment of compensated stage of liver cirrhosis.Methods:100 patients were randomly divided into 50 cases in the observation group and 50 cases in the control group.On the basis of conventional treatment,the observation group was orally administered with the traditional Chinese medicine Qijia Ruangan pill,and the control group was orally administered with Anluo Huaxian pill,and both groups were treated for 3 months.Fibroscan elasticity value,spleen length,spleen thickness,portal vein trunk internal diameter,splenic vein internal diameter,albumin transaminase(AST),alanine transaminase(ALT),total bilirubin(TBIL) were measured before and after the treatment.And the Chinese medicine symptom scores and the comprehensive therapeutic efficacy were evaluated,respectively.Results:The efficacy of the observation group was significantly better than that of the control group(P<0.05).After treatment,the scores of TCM symptoms in the observation group was lower than that in the control group(P<0.05).The Fibroscan elasticity of the observation group and the control group after treatment was significantly lower than that before treatment,and the observation group was lower than the control group(all P<0.05).After treatment,the liver function indexes AST,TBIL and ALT in the observation group were significantly lower than those before treatment(all P<0.05),and the improvement degree of AST was significantly better than that of the control group(P<0.05).After treatment,the portal vein diameter,splenic vein diameter,spleen thickness and spleen length in the observation group were significantly decreased compared with those before treatment(all P<0.05),and the improvement of portal vein diameter in the observation group was significantly better than that in the control group(P<0.05).Conclusion:Qijia Ruangan pill can effectively improve the liver function of patients with cirrhosis in the compensatory stage,relieve clinical symptoms,and delay the process of cirrhosis,with significant clinical efficacy and no obvious adverse reactions.